Open Access via the Elsevier Agreement We are grateful to the EAU Research Foundation for funding the project. The sponsor played a role in review of the manuscript.Peer reviewedPublisher PD
Copyright © 2015 Maria Jose ́ Ribal et al.This is an open access article distributed under theCreati...
BACKGROUND: There is uncertainty in deferred active treatment (DAT) programmes, regarding patient se...
International audienceThe safety profile of androgen deprivation therapy (ADT) is well known, and ca...
Background: Evidence-practice gaps exist in urology. We previously surveyed European Association of ...
Background: Guidelines on androgen deprivation therapy (ADT) for prostate cancer (PCa) arise from a ...
OBJECTIVE: To evaluate both the patterns of prescription of androgen deprivation therapy (ADT) in pa...
To evaluate both the patterns of prescription of androgen deprivation therapy (ADT) in patients with...
Item does not contain fulltextOBJECTIVE: To explore preferences in the management of patients with n...
ObjectiveTo evaluate both the patterns of prescription of androgen deprivation therapy (ADT) in pati...
The authors are grateful to the following individuals and organisations for the following contributi...
Background: According to (inter-)national guidelines, (neo-)adjuvant and concurrent androgen depriva...
OBJECTIVE: Our aim was to present a summary of the 2010 version of the European Association of Urolo...
Background: Androgen deprivation therapy (ADT) is a non-curative but essential treatment of prostate...
none69siBackground: There is uncertainty in deferred active treatment (DAT) programmes, regarding p...
Item does not contain fulltextBACKGROUND: Evidence-based recommendations are available for the manag...
Copyright © 2015 Maria Jose ́ Ribal et al.This is an open access article distributed under theCreati...
BACKGROUND: There is uncertainty in deferred active treatment (DAT) programmes, regarding patient se...
International audienceThe safety profile of androgen deprivation therapy (ADT) is well known, and ca...
Background: Evidence-practice gaps exist in urology. We previously surveyed European Association of ...
Background: Guidelines on androgen deprivation therapy (ADT) for prostate cancer (PCa) arise from a ...
OBJECTIVE: To evaluate both the patterns of prescription of androgen deprivation therapy (ADT) in pa...
To evaluate both the patterns of prescription of androgen deprivation therapy (ADT) in patients with...
Item does not contain fulltextOBJECTIVE: To explore preferences in the management of patients with n...
ObjectiveTo evaluate both the patterns of prescription of androgen deprivation therapy (ADT) in pati...
The authors are grateful to the following individuals and organisations for the following contributi...
Background: According to (inter-)national guidelines, (neo-)adjuvant and concurrent androgen depriva...
OBJECTIVE: Our aim was to present a summary of the 2010 version of the European Association of Urolo...
Background: Androgen deprivation therapy (ADT) is a non-curative but essential treatment of prostate...
none69siBackground: There is uncertainty in deferred active treatment (DAT) programmes, regarding p...
Item does not contain fulltextBACKGROUND: Evidence-based recommendations are available for the manag...
Copyright © 2015 Maria Jose ́ Ribal et al.This is an open access article distributed under theCreati...
BACKGROUND: There is uncertainty in deferred active treatment (DAT) programmes, regarding patient se...
International audienceThe safety profile of androgen deprivation therapy (ADT) is well known, and ca...